To Essentsiforta

General characteristics. Structure:

Active ingredient: 300 mg of "essential" phospholipids in the form of a lipoid of PPL-600.

Structure of a cover of the capsule: gelatin, glycerin, the water purified Natrium benzoicum of E-211, titanium E-171 dioxide, dyes: ferrous oxide red E-172, ferrous oxide yellow E-172, ferrous oxide black E-172.

Drug for treatment of diseases of a liver.

Pharmacological properties:

Pharmacodynamics. Damage of membranes of hepatic cells and their organellas can take place at all diseases of a liver that can lead to disturbance of activity of membranes - the connected enzymes and receptor systems, to disturbance of metabolic function of cells and decrease in regeneration of a liver. The chemical structure of the phospholipids which are a part of drug to Essentsiforta corresponds that for endogenous phospholipids, but they surpass the last thanks to high content in them polyunsaturated (essential) fatty acids. Inclusion of these high-energy molecules mainly in fraction of membranes of hepatic cells promotes regeneration of the damaged hepatic fabric. As cis-double bonds of their half-yen acids warn a parallel arrangement of hydrocarbon chains of membranes of phospholipids, density of an arrangement of phospholipidic structures is weakened that increases metabolic rate. Functional units from membranes - the connected enzymes which can increase the activity are formed and provide course of the main metabolic processes in the physiological way. Phospholipids interfere with the broken lipid metabolism by regulation of metabolism of lipoproteins in such a way that neutral fats and cholesterol pass into the transported forms, generally due to increase cholesterol - the connecting ability of LPVP, and, thus, can be subject to oxidation. In the course of excretion of phospholipids through biliary system the litogenny index decreases and there is a bile stabilization.

Pharmacokinetics. More than 90% of the phospholipids accepted orally are absorbed in a small intestine. Most of them is split by a phospholipase And to 1-acyl-lizofosfatidilkholina which 50% reatsilirutsya even in the course of absorption in mucous intestines directly in polyunsaturated phosphatidylsincaline. This polyunsaturated phosphatidylsincaline gets into blood in lymphatic ways and from there - mainly in the connected state with LPVP - it comes, in particular, to a liver. The maximum level of phosphatidylsincaline in blood after oral administration, составляющийв average 20%, is reached 6-24 hours later. The period of semi-life of a choline component makes 66 hours, and that for unsaturated fatty acids - 32 hours.

Indications to use:

To Essentsiforta is the drug from raw materials of a plant origin used for treatment of diseases of a liver.

It is used at patients with various alimentary and toxic damages of a liver which are listed below for reduction of such symptoms as loss of appetite and/or heavy feeling in right hypochondrium which can demonstrate the following defeats and/or a disease of a liver:
• fatty degeneration of a liver (also at diabetes);
• hepatitises of any nature, acute and chronic;
• cirrhoses;
• toxic damages of a liver, including an alcoholic liver disease, medicinal damages of a liver.

Route of administration and doses:

For teenagers 12 years and with a body weight more than 43 kg, and also for adults are more senior: an initial dose - 3 times a day on 2 capsules not less than 3 months, a maintenance dose - 3 times a day on one capsule not less than 4 weeks.

The attending physician can recommend other dosage and duration of treatment, depending on a condition of the patient and disease.

To accept capsules during meal, without chewing, washing down with a small amount of water.

Features of use:

Use during pregnancy and during breastfeeding. Use of drug according to indications, but only according to the recommendation of the doctor is possible.

Does not influence a possibility of driving of the car, work with the equipment.

Side effects:

Very seldom at reception of the raised doses to Essentsiforta there can be a gastrointestinal frustration (diarrhea).

Interaction with other medicines:

So far are unknown.

Contraindications:

- hypersensitivity to drug components;
- children's age up to 12 years;
- the states connected with risk of development of cardiovascular diseases as administration of drugs, containing phosphotidylsincaline (phospholipids), can lead to increase in level of trimethylamine-N-oxide in blood and urine that increases risk of emergence of the undesirable phenomena from cardiovascular system.

Overdose:

So far messages on the reactions connected with peredozirovyoky or intoxication symptoms when using drug, it is not revealed.

Storage conditions:

To store in the place protected from moisture and light at a temperature not above 21 °C. To store in the place, unavailable to children. Period of validity 2 years.

Issue conditions:

Without recipe

Packaging:

On 10 capsules in a planimetric cell upakovyoka, on 3 or 5 blister strip packagings in a pack.